about
Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitorsOptimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.Picomolar dichotomous activity of gnidimacrin against HIV-1.Anti-AIDS agents 79. Design, synthesis, molecular modeling and structure-activity relationships of novel dicamphanoyl-2',2'-dimethyldihydropyranochromone (DCP) analogs as potent anti-HIV agents.Synthesis and proteasome inhibition of lithocholic acid derivativesPotential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.Anti-AIDS agents 85. Design, synthesis, and evaluation of 1R,2R-dicamphanoyl-3,3-dimethyldihydropyrano-[2,3-c]xanthen-7(1H)-one (DCX) derivatives as novel anti-HIV agents.Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variantsDesign, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agentsProteasome regulators: activators and inhibitors.Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors.Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.Activation and inhibition of the proteasome by betulinic acid and its derivatives.Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles.Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives.Phenolic diterpenoid derivatives as anti-influenza a virus agents.Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides.Identification and synthesis of quinolizidines with anti-influenza a virus activity.Structure of a tethered cationic 3-aminopropyl chain incorporated into an oligodeoxynucleotide: evidence for 3'-orientation in the major groove accompanied by DNA bending.Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564.Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitorDiscovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome
P50
Q33814879-1E357425-6031-47C3-AED4-DBA549D373B4Q33860320-BADFB939-3FF5-48EC-A8C2-D51BFEFAD153Q34062554-ABEFD1E0-C4C4-4DBF-9FA5-26BEED66A67AQ34196540-256868B4-9E4E-4DA9-A8F9-91D826913094Q34769338-20CCCA0B-8761-4985-89D9-79C22C7C03E0Q35137657-80D3A4B1-EB8D-4F78-9CB7-3515DC8C95A9Q35524888-2809B363-16E2-4396-8DED-EA8F6A4285F8Q35548195-2E052DF4-3757-4620-919F-9A112FBB1A20Q35675215-17C7A2CE-FBAC-4CD8-8E55-CA2B623EC11DQ36185528-779ABFBE-96A1-4D0A-94D2-51D407656B48Q36292585-0DF924B2-E4D4-404D-ADB2-F7FA04B270F1Q36340098-A451F042-9514-4A1F-BA1F-FA6F58342BB7Q36691642-61F54547-FA85-4416-990B-5B9E36534940Q37330178-A4A5D4D4-0479-4568-AD3E-F671CB1B385AQ37411350-A047EBAF-89C4-4001-AE82-37DCB38E3D08Q39375880-A3858437-7808-4D77-A4EB-0776972D1F73Q39382195-EBB4A401-61AA-459C-8695-266ECDD8ED19Q40063752-7ED3878A-ED19-479D-8A25-8211FEFD6525Q40074485-843FAD19-967A-43CB-96C0-106482AF40DCQ40357793-ABA08865-BE05-459D-9850-9DAFA388E574Q40464008-6F0F0F0D-99AA-42DA-872F-0BABD758428EQ41377963-DE07113C-A429-4720-8C2F-4FD86FE1B3B8Q41440361-16669E97-D3DB-4B55-9F83-D2F9E9263C30Q42198553-894BB598-85E7-4D4D-8244-953385B7953EQ44066239-2D6AE0A7-A461-4BAD-A4AC-5C73348CDADBQ46824829-6B4CBC75-DC2C-4D3C-B4F2-DB09AB4C374AQ47318968-3FB6957C-0AF6-413D-9D38-A47E4DD35978Q79690094-558DC472-238A-4FB9-8B53-054DE47152A1Q85201856-F2E2C20C-2BB6-4C85-B9CB-592EB74CB965
P50
description
researcher
@en
հետազոտող
@hy
name
Li Huang
@ast
Li Huang
@en
Li Huang
@es
Li Huang
@nl
Li Huang
@sl
type
label
Li Huang
@ast
Li Huang
@en
Li Huang
@es
Li Huang
@nl
Li Huang
@sl
prefLabel
Li Huang
@ast
Li Huang
@en
Li Huang
@es
Li Huang
@nl
Li Huang
@sl
P106
P1153
7404735845
P31
P496
0000-0001-5659-4053